Ireland
--:--IST
Priya Life Science Medicines register
Registers› Irish medicines ›Karvea 150 mg tablets
Medicines register · Ireland

Karvea 150 mg tablets

Authorisation EU/1/97/049/004-006 · Sanofi Winthrop Industrie

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. HPRA list dated 19 Nov 2026
Licence holder
Sanofi Winthrop Industrie (all products →)
Active substance
Irbesartan
Clinical trials
4 clinical trials →
Dosage form
Tablet
Route of administration
Oral use
ATC codes
C09CA, C09CA04
Prescription status
Product subject to prescription which may be renewed (B)
Supply
Supply through pharmacies only
Legal basis
Full application (Article 8(3) of Directive No 2001/83/EC)

Irbesartan: supply and approvals

51 authorised products on the HPRA list contain Irbesartan. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 18 Nov 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 18 Nov 2026)
Germany (BfArM)
No entry in the BfArM supply notices (checked 18 Nov 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

About this licence

Centralised EU authorisation. This product holds an EU-wide marketing authorisation granted by the European Commission after assessment by the European Medicines Agency, valid in every EU country. Its EU product number is 049. The HPRA list does not say whether it is on sale.

Open the European Commission’s Union Register record →

Other medicines with Irbesartan in Ireland

50 other products on the HPRA list contain Irbesartan, from 8 licence holders; 6 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
Irbesartan Clonmel 150 mg film-coated tabletsClonmel Healthcare LtdNational authorisation (PA)Marketed
Irbesartan Clonmel 300 mg film-coated tabletsClonmel Healthcare LtdNational authorisation (PA)Marketed
Irbesartan Clonmel 75 mg film-coated tabletsClonmel Healthcare LtdNational authorisation (PA)Marketed
Irbesartan Rowa 150 mg tabletsRowa Pharmaceuticals Limited,National authorisation (PA)Marketed
Irbesartan Rowa 300 mg tabletsRowa Pharmaceuticals Limited,National authorisation (PA)Marketed
Irbesartan Rowa 75 mg tabletsRowa Pharmaceuticals Limited,National authorisation (PA)Marketed
Aprovel 150 mg film-coated tabletsSanofi Winthrop IndustrieCentralised EU authorisationNot stated
Aprovel 150 mg tabletsSanofi Winthrop IndustrieCentralised EU authorisationNot stated
Aprovel 300 mg film-coated tabletsSanofi Winthrop IndustrieCentralised EU authorisationNot stated
Aprovel 300 mg tabletsSanofi Winthrop IndustrieCentralised EU authorisationNot stated
Aprovel 75 mg film-coated tabletsSanofi Winthrop IndustrieCentralised EU authorisationNot stated
Aprovel 75 mg tabletsSanofi Winthrop IndustrieCentralised EU authorisationNot stated

All 51 products with Irbesartan →

Other substances in ATC group C09CA

The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 9 other active substances share the group C09CA with this product:

Telmisartan (34) · Valsartan (26) · Candesartan cilexetil (21) · Losartan potassium (18) · Olmesartan medoxomil (18) · Hydrochlorothiazide (4) · Azilsartan medoxomil (3) · Eprosartan (3) · Hydrocholothiazide (1)

Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.

The licence holder

Sanofi Winthrop Industrie holds 91 products on the HPRA list, with 75 different active substances; 7 of the products are marked as marketed.

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 19 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.